Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Jul;40(1):43–50. doi: 10.1111/j.1365-2125.1995.tb04533.x

Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets.

J A Cooper 1, S J Hill 1, S P Alexander 1, P C Rubin 1, E H Horn 1
PMCID: PMC1365026  PMID: 8527267

Abstract

1. We have assessed the effects of adenosine receptor agonists and antagonists on collagen-induced 5-hydroxytryptamine (5-HT) release and cyclic AMP generation in human platelets. 2. 5'-N-ethylcarboxamidoadenosine (NECA) and CGS 21680 elicited accumulations of cyclic AMP with mean EC50 values of 2678 and 980 nM, respectively. The maximal response to CGS 21680 was approximately half that of the response to 10 microM NECA. 3. NECA and CGS 21680 inhibited collagen-induced 5-hydroxytryptamine release with mean EC50 values of 960 and 210 nM, respectively. The maximal response to CGS 21680 was approximately 25% of the response to 10 microM NECA. 4. The A1/A2a-selective adenosine receptor antagonist PD 115,199 was more potent as an inhibitor of NECA-elicited responses than the A1-selective antagonist DPCPX with calculated Ki values of 22-32 nM and > 10 microM, respectively. 5. In the presence of a cyclic AMP phosphodiesterase inhibitor, the effects of CGS 21680 on cyclic AMP accumulation and 5-HT release were enhanced to levels similar to those elicited by 10 microM NECA. In the absence of phosphodiesterase inhibition, CGS 21680 did not antagonise the effects of NECA. Furthermore, endogenous adenosine did not contribute to the effects of CGS 21680 when phosphodiesterase was inhibited. 6. We conclude that an A2a adenosine receptor appears to be involved in the NECA-elicited increases in cyclic AMP levels and inhibition of 5-HT release in human platelets.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
43

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander S. P., Losinski A., Kendall D. A., Hill S. J. A comparison of A2 adenosine receptor-induced cyclic AMP generation in cerebral cortex and relaxation of pre-contracted aorta. Br J Pharmacol. 1994 Jan;111(1):185–190. doi: 10.1111/j.1476-5381.1994.tb14042.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BORN G. V., CROSS M. J. THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963 Aug;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bruns R. F., Fergus J. H., Badger E. W., Bristol J. A., Santay L. A., Hartman J. D., Hays S. J., Huang C. C. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):59–63. doi: 10.1007/BF00165037. [DOI] [PubMed] [Google Scholar]
  4. Bruns R. F., Fergus J. H., Badger E. W., Bristol J. A., Santay L. A., Hays S. J. PD 115,199: an antagonist ligand for adenosine A2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):64–69. doi: 10.1007/BF00165038. [DOI] [PubMed] [Google Scholar]
  5. Camm A. J., Garratt C. J. Adenosine and supraventricular tachycardia. N Engl J Med. 1991 Dec 5;325(23):1621–1629. doi: 10.1056/NEJM199112053252306. [DOI] [PubMed] [Google Scholar]
  6. Collis M. G., Hourani S. M. Adenosine receptor subtypes. Trends Pharmacol Sci. 1993 Oct;14(10):360–366. doi: 10.1016/0165-6147(93)90094-z. [DOI] [PubMed] [Google Scholar]
  7. Cusack N. J., Hourani S. M. 5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation. Br J Pharmacol. 1981 Mar;72(3):443–447. doi: 10.1111/j.1476-5381.1981.tb10995.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edlund A., Sidén A., Sollevi A. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. Thromb Res. 1987 Jan 15;45(2):183–190. doi: 10.1016/0049-3848(87)90172-1. [DOI] [PubMed] [Google Scholar]
  9. Emmons P. R., Harrison M. J., Honour A. J., Mitchell J. R. Effect of dipyridamole on human platelet behaviour. Lancet. 1965 Sep 25;2(7413):603–606. doi: 10.1016/s0140-6736(65)90515-5. [DOI] [PubMed] [Google Scholar]
  10. Feoktistov I., Biaggioni I. Characterization of adenosine receptors in human erythroleukemia cells and platelets: further evidence for heterogeneity of adenosine A2 receptor subtypes. Mol Pharmacol. 1993 Jun;43(6):909–914. [PubMed] [Google Scholar]
  11. FitzGerald G. A. Dipyridamole. N Engl J Med. 1987 May 14;316(20):1247–1257. doi: 10.1056/NEJM198705143162005. [DOI] [PubMed] [Google Scholar]
  12. Furlong T. J., Pierce K. D., Selbie L. A., Shine J. Molecular characterization of a human brain adenosine A2 receptor. Brain Res Mol Brain Res. 1992 Sep;15(1-2):62–66. doi: 10.1016/0169-328x(92)90152-2. [DOI] [PubMed] [Google Scholar]
  13. Harrison M. J., Pollock S. S., Steiner M., Weisblatt E. Inhibitors of "spontaneous" platelet aggregation in whole blood. Atherosclerosis. 1985 Dec;58(1-3):199–203. doi: 10.1016/0021-9150(85)90066-8. [DOI] [PubMed] [Google Scholar]
  14. Haslam R. J., McClenaghan M. D. Measurement of circulating prostacyclin. Nature. 1981 Jul 23;292(5821):364–366. doi: 10.1038/292364a0. [DOI] [PubMed] [Google Scholar]
  15. Haslam R. J., Rosson G. M. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol. 1975 Sep;11(5):528–544. [PubMed] [Google Scholar]
  16. Heptinstall S., Bevan J., Cockbill S. R., Hanley S. P., Parry M. J. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res. 1980 Oct 15;20(2):219–230. doi: 10.1016/0049-3848(80)90387-4. [DOI] [PubMed] [Google Scholar]
  17. Horn E. H., Cooper J., Hardy E., Heptinstall S., Rubin P. C. A cross-sectional study of platelet cyclic AMP in healthy and hypertensive pregnant women. Clin Sci (Lond) 1991 Jun;80(6):549–558. doi: 10.1042/cs0800549. [DOI] [PubMed] [Google Scholar]
  18. Hüttemann E., Ukena D., Lenschow V., Schwabe U. Ra adenosine receptors in human platelets. Characterization by 5'-N-ethylcarboxamido[3H]adenosine binding in relation to adenylate cyclase activity. Naunyn Schmiedebergs Arch Pharmacol. 1984 Mar;325(3):226–233. doi: 10.1007/BF00495948. [DOI] [PubMed] [Google Scholar]
  19. Jacobson K. A., van Galen P. J., Williams M. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J Med Chem. 1992 Feb 7;35(3):407–422. doi: 10.1021/jm00081a001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lohse M. J., Klotz K. N., Lindenborn-Fotinos J., Reddington M., Schwabe U., Olsson R. A. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1987 Aug;336(2):204–210. doi: 10.1007/BF00165806. [DOI] [PubMed] [Google Scholar]
  21. Lohse M. J., Klotz K. N., Lindenborn-Fotinos J., Reddington M., Schwabe U., Olsson R. A. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1987 Aug;336(2):204–210. doi: 10.1007/BF00165806. [DOI] [PubMed] [Google Scholar]
  22. Londos C., Cooper D. M., Wolff J. Subclasses of external adenosine receptors. Proc Natl Acad Sci U S A. 1980 May;77(5):2551–2554. doi: 10.1073/pnas.77.5.2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lupica C. R., Cass W. A., Zahniser N. R., Dunwiddie T. V. Effects of the selective adenosine A2 receptor agonist CGS 21680 on in vitro electrophysiology, cAMP formation and dopamine release in rat hippocampus and striatum. J Pharmacol Exp Ther. 1990 Mar;252(3):1134–1141. [PubMed] [Google Scholar]
  24. Paul S., Feoktistov I., Hollister A. S., Robertson D., Biaggioni I. Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: evidence that both effects are coupled to adenylate cyclase. Mol Pharmacol. 1990 Jun;37(6):870–875. [PubMed] [Google Scholar]
  25. Peakman M. C., Hill S. J. Adenosine A2B-receptor-mediated cyclic AMP accumulation in primary rat astrocytes. Br J Pharmacol. 1994 Jan;111(1):191–198. doi: 10.1111/j.1476-5381.1994.tb14043.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pierce K. D., Furlong T. J., Selbie L. A., Shine J. Molecular cloning and expression of an adenosine A2b receptor from human brain. Biochem Biophys Res Commun. 1992 Aug 31;187(1):86–93. doi: 10.1016/s0006-291x(05)81462-7. [DOI] [PubMed] [Google Scholar]
  27. Quattrin S., Genovese A., Cirillo R., Formisano S., Marone G. Functional and biochemical evidence of a specific adenosine A2/Ra receptor on human platelets. Ric Clin Lab. 1988 Apr-Sep;18(2-3):105–118. doi: 10.1007/BF02918878. [DOI] [PubMed] [Google Scholar]
  28. Schrader J., Berne R. M., Rubio R. Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol. 1972 Jul;223(1):159–166. doi: 10.1152/ajplegacy.1972.223.1.159. [DOI] [PubMed] [Google Scholar]
  29. Sills T., Heptinstall S. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Thromb Haemost. 1986 Jun 30;55(3):305–308. [PubMed] [Google Scholar]
  30. Stiles G. L. Adenosine receptors and beyond: molecular mechanisms of physiological regulation. Clin Res. 1990 Jan;38(1):10–18. [PubMed] [Google Scholar]
  31. Söderbäck U., Sollevi A., Wallen N. H., Larsson P. T., Hjemdahl P. Anti-aggregatory effects of physiological concentrations of adenosine in human whole blood as assessed by filtragometry. Clin Sci (Lond) 1991 Nov;81(5):691–694. doi: 10.1042/cs0810691. [DOI] [PubMed] [Google Scholar]
  32. Williams M. Purine receptors in mammalian tissues: pharmacology and functional significance. Annu Rev Pharmacol Toxicol. 1987;27:315–345. doi: 10.1146/annurev.pa.27.040187.001531. [DOI] [PubMed] [Google Scholar]
  33. van Calker D., Müller M., Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem. 1979 Nov;33(5):999–1005. doi: 10.1111/j.1471-4159.1979.tb05236.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES